Virios to advance development of combination therapy for long Covid
IMC-2 is a combination of valacyclovir and celecoxib and its Phase 2 programme is expected to start in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Jan 24
IMC-2 is a combination of valacyclovir and celecoxib and its Phase 2 programme is expected to start in…
23 Jan 24
The MHRA conducted a thorough review into the effectiveness of current measures to reduce the risk of potentially…
22 Jan 24
The decision from NICE marks a shift from its previous preliminary stance of not supporting the use of…
22 Jan 24
Bogutai, created in partnership with the Swiss company Ypsomed, features a pre-filled structural design and is intended for…
19 Jan 24
Study demonstrated the DMT’s effectiveness as a melanoma rule-out test for all skin types
18 Jan 24
Upon completion of the merger, expected to be completed in the first half of this year, Taro will…
18 Jan 24
The Gibco CTS Cellmation Software is designed to connect and integrate workflows across several Thermo Fisher Scientific cell…
17 Jan 24
Rad AI will use Google Cloud’s platform and AI tools, including MedLM, a family of foundation models fine-tuned…
17 Jan 24
The US FDA has approved Hyqvia as a maintenance therapy to inhibit the relapse of neuromuscular disability and…
17 Jan 24
Previously known as CTX-001, Casgevy is a non-viral ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with…